Ga-PSMA PET/CT for Patients with PSA Relapse After Radical Prostatectomy or External Beam Radiotherapy

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2021 Apr 3

PMID 33808350

Citations 5

Authors

Finn Edler von Eyben

Cigdem Soydal

Rie von Eyben

Affiliations

Soon will be listed here.

Abstract

The study aimed to summarize clinical characteristics associated with Gallium-68-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (Ga-PSMA PET/CT) scans as patients were restaged for prostate-specific antigen (PSA) relapse after radical prostatectomy (RP) or external beam radiotherapy (EBRT). Our analyses included multiple cox regression analyses. The study evaluated 95 patients with rising values of PSAs after RP and after EBRT. Sixty 63% of patients had a positive Ga-PSMA PET/CT scan. Twelve patients (13%) had a positive site in the prostate bed, 29 patients (30%) had a positive site in the regional lymph nodes, and 19 (20%) had positive sites in distant organs. After four years follow-up, 21 patients (22%) died. Using multiple Cox regression analyses, the number of positive sites on the Ga-PSMA PET/CT scan significantly predicted overall survival (OS) ( = 0.0001), whereas risk score and regional locations of the positive sites were not significant in the multiple Cox regression analyses. Our study indicates that the specific findings of Ga-PSMA PET/CT scans are important because detailed findings of the scans predict the outcome after salvage treatment of patients with PSA relapse examined with Ga-PSMA PET/CT scans.

Citing Articles

Necessity of Pelvic Lymph Node Irradiation in Patients with Recurrent Prostate Cancer after Radical Prostatectomy in the PSMA PET/CT Era: A Narrative Review.

Nabian N, Ghalehtaki R, Counago F Biomedicines. 2023; 11(1).

PMID: 36672547 PMC: 9855373. DOI: 10.3390/biomedicines11010038.

A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis.

von Eyben R, Kapp D, Hoffmann M, Soydal C, Uprimny C, Virgolini I Cancers (Basel). 2022; 14(21).

PMID: 36358880 PMC: 9657957. DOI: 10.3390/cancers14215461.

On the Way for Patients with Prostate Cancer to the Best Use of PSMA.

von Eyben F, Bauman G, Kapp D, Virgolini I, Paganelli G Int J Mol Sci. 2022; 23(5).

PMID: 35269620 PMC: 8909989. DOI: 10.3390/ijms23052478.

PSMA PET in Imaging Prostate Cancer.

Tsechelidis I, Vrachimis A Front Oncol. 2022; 12:831429.

PMID: 35155262 PMC: 8832487. DOI: 10.3389/fonc.2022.831429.

Differences in Distribution and Detection Rate of the [Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11-Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer.

Guhne F, Radke S, Winkens T, Kuhnel C, Greiser J, Seifert P Pharmaceuticals (Basel). 2022; 15(1).

PMID: 35056066 PMC: 8779232. DOI: 10.3390/ph15010009.

References

Verburg F, Pfister D, Heidenreich A, Vogg A, Drude N, Voo S . Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2015; 43(3):397-403. DOI: 10.1007/s00259-015-3240-1. View

Gandaglia G, Leni R, Fossati N, Cucchiara V, Montorsi F, Briganti A . Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond. Eur Urol Focus. 2021; 7(2):245-249. DOI: 10.1016/j.euf.2020.12.014. View

Cantiello F, Crocerossa F, Russo G, Gangemi V, Ferro M, Vartolomei M . Comparison Between Cu-PSMA-617 PET/CT and F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence. Clin Genitourin Cancer. 2018; 16(5):385-391. DOI: 10.1016/j.clgc.2018.05.014. View

Morigi J, Stricker P, van Leeuwen P, Tang R, Ho B, Nguyen Q . Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med. 2015; 56(8):1185-90. DOI: 10.2967/jnumed.115.160382. View

Afshar-Oromieh A, Avtzi E, Giesel F, Holland-Letz T, Linhart H, Eder M . The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 42(2):197-209. PMC: 4315487. DOI: 10.1007/s00259-014-2949-6. View

Artibani W, Porcaro A, De Marco V, Cerruto M, Siracusano S . Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review. Urol Int. 2017; 100(3):251-262. DOI: 10.1159/000481438. View

Akdemir E, Tuncel M, Akyol F, Bilen C, Baydar D, Karabulut E . Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer. World J Urol. 2018; 37(5):813-821. DOI: 10.1007/s00345-018-2460-y. View

Eissa A, Elsherbiny A, Coelho R, Rassweiler J, Davis J, Porpiglia F . The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urol Nefrol. 2018; 70(5):462-478. DOI: 10.23736/S0393-2249.18.03081-3. View

Morris M, Rowe S, Gorin M, Saperstein L, Pouliot F, Josephson D . Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res. 2021; 27(13):3674-3682. PMC: 8382991. DOI: 10.1158/1078-0432.CCR-20-4573. View

10.

Fizazi K, Shore N, Tammela T, Ulys A, Vjaters E, Polyakov S . Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019; 380(13):1235-1246. DOI: 10.1056/NEJMoa1815671. View

11.

Hoffmann M, Buchholz H, Wieler H, Hofner T, Muller-Hubenthal J, Trampert L . The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Oncotarget. 2019; 10(58):6124-6137. PMC: 6817454. DOI: 10.18632/oncotarget.27239. View

12.

Cookson M, Aus G, Burnett A, Canby-Hagino E, DAmico A, Dmochowski R . Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in.... J Urol. 2007; 177(2):540-5. DOI: 10.1016/j.juro.2006.10.097. View

13.

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

14.

McCarthy M, Francis R, Tang C, Watts J, Campbell A . A Multicenter Prospective Clinical Trial of Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging. Int J Radiat Oncol Biol Phys. 2019; 104(4):801-808. DOI: 10.1016/j.ijrobp.2019.03.014. View

15.

Celli M, De Giorgi U, Caroli P, Di Iorio V, Fantini L, Rossetti V . Clinical value of negative Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020; 48(1):87-94. DOI: 10.1007/s00259-020-04914-8. View

16.

Evangelista L, Zattoni F, Cassarino G, Artioli P, Cecchin D, Dal Moro F . PET/MRI in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2020; 48(3):859-873. PMC: 8036222. DOI: 10.1007/s00259-020-05025-0. View

17.

Tulsyan S, Das C, Tripathi M, Seth A, Kumar R, Bal C . Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. Nucl Med Commun. 2017; 38(12):1094-1102. DOI: 10.1097/MNM.0000000000000749. View

18.

Emmett L, Tang R, Nandurkar R, Hruby G, Roach P, Watts J . 3-Year Freedom from Progression After Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. J Nucl Med. 2019; 61(6):866-872. DOI: 10.2967/jnumed.119.235028. View

19.

Pienta K, Gorin M, Rowe S, Carroll P, Pouliot F, Probst S . A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with F-DCFPyL in Prostate Cancer Patients (OSPREY). J Urol. 2021; 206(1):52-61. PMC: 8556578. DOI: 10.1097/JU.0000000000001698. View

20.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U . Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018; 378(26):2465-2474. PMC: 8288034. DOI: 10.1056/NEJMoa1800536. View